Enter the word to search and press enter.
Building CReSA. Campus UAB.
08193 Bellaterra (Barcelona) Spain.
Latitude: 41º 30′ 18,637″
Longitude: 2º 5′ 54,257″
Tel: (+34) 93 467 40 40 +Ext. 1708
Fax: 93 581 44 90
Follow IRTA-CReSA on the social networks:
CReSA has always pursued the implementation of Quality in its activities. For that purpose, a Quality Assurance Unit (QAU) was created early before the start of activities at the new building in 2005.
In year 2009, CReSA was certified as a research laboratory complying with Good Laboratory Practices (GLP) and registered in the GLP Verification Program with number BPL050CAT. It complies with the Royal decree 822/1993, which sets the principles of good laboratory practice and its application in non-clinical studies. Moreover, studies with animals out from the own animal facilities follow the principles of Good Clinical Practices (GCPs).
This is in application in studies that CReSA carries out in the following fields:
CReSA is periodically inspected by the Subdirectorate-General for Healthcare and Pharmaceutical Planning and Quality (Government of Catalonia, Spain), which is the competent authority for the control in the application of these principles in the field of veterinary drugs in Catalonia, according to the Royal decree 2043/1994 October 14th on the inspection and the verification of good laboratory practice (modified by the order of the Ministry of Presidency of April 14th 2000).
CReSA is conducting diagnostic tests for the Catalonian Government. Preparatory work by QAU was performed in 2007 and 2008 to ask ENAC (Spanish Accreditation Entity) for accreditation of diagnostic techniques and procedures. In 2009, an inspection visit leaded to the final accreditation by recognition of the technical competition according to the criteria in UNE-EN ISO/IEC 17025 for the performance of diagnostics tests with accreditation number 900/LE1557.
The inspection of the year 2019 accredits the CReSA in the new UNE-EN ISO/IEC 17025: 2017 was obtained to perform diagnosis for:
In 2015, CReSA was certified as a research laboratory that has a quality management system in accordance with ISO 9001: 2015 and was registered with IRTA under number ER-0591/2013 by IQNet (The International Certification Network) and AENOR (Spanish Association for Standardization and Certification).
On 26 May 2017, the General Assembly of the World Organization for Animal Health (OIE) designated the Animal Health Research Center (IRTA-CReSA) as the OIE Collaborating Center for “research and control of emerging swine diseases and re-emerging in Europe, ”with Dr. Joaquim Segalés as contact person, and OIE Reference Laboratory for Classical Swine Fever, with Dr. Llilianne Ganges as a designated expert. It was the first research center in Spain designated as a member of the OIE Center network.
The OIE is a global organization that defines Collaborating Centers as centers of expertise in a specific area of expertise related to general animal health issues. In the competition for emerging and re-emerging pig diseases, IRTA-CReSA can provide international advice following the mandate and internal regulations of the OIE Collaborating Centers.
The appointment was made possible by the Ministry of Agriculture and Fisheries, Food and Environment (Mapam), in charge of presenting the candidacy represented by Mr. Valentín Almansa (Director General of Health of Agricultural Production), Mrs. Beatriz Muñoz (Deputy Director General of Animal Health and Hygiene and Traceability) and Mr. Gregorio Torres (Delegate of the OIE Scientific and Technical Department, appointed by Mapam).
The Network of High-Security Biological Laboratories (RLASB) is one of the Singular Scientific and Technical Infrastructures (ICTS) of Spain, constituted by two nodes, IRTA-CReSA and CISA-INIA. It provides open access research facilities under BSL3 conditions. ICTS are large installations, resources, facilities and services, unique in its kind, that are dedicated to cutting edge and high quality research and technological development, as well as to promote exchange, transmission and preservation of knowledge, technology transfer and innovation.
TRANSVAC2 is designed to accelerate vaccine development by enhancing European vaccine research and training, and increase sustainability of EC vaccine projects by implementing a permanent research infrastructure for early vaccine development. It is a collaborative infrastructure project funded by the European Commission, initially under the 7th Framework Programme (FP7) and currently under Horizon 2020. The project is a joint effort of leading European groups working in the field of vaccine development and is coordinated by the European Vaccine Initiative (EVI).
Infravec2 is an international and interdisciplinary research infrastructure project funded by the European Commission Horizon 2020 Research Infrastructure Program (INFRAIA). Infravec2 provides NO COST access to products and services for research on insect vectors of human and animal disease, including mosquitoes, sandflies and other flies. Infravec2 is coordinated by the Institut Pasteur, Paris, France.
The principal aim of the VetBioNet infrastructure project is to establish and maintain a comprehensive network of pre-eminent high-containment (BSL3) research facilities, academic institutes, international organizations and industry partners that is dedicated to advance research on epizootic and zoonotic diseases and to promote technological developments.